"Swot Analysis of Pharmaceutical Company"
Takeda Pharmaceutical Co. Ltd. “SWOT is an acronym for the internal Strengths and Weaknesses of a firm and the environmental Opportunities and Threats facing that firm. SWOT analysis is a widely used technique through which managers create a quick overview of a company’s strategic situation. The technique is based on the assumption that an effective strategy derives from a sound “fit” between a firm’s internal resources (strengths and weaknesses) and its external situation (opportunities and threats). A good fit maximizes a firm’s strengths and opportunities and minimizes its weaknesses and threats. Accurately applied, this simple assumption has powerful implications for the design of a successful strategy.” Takeda Pharmaceutical Co. Ltd. Takeda Pharmaceutical (Takeda), the largest pharmaceutical company in Japan, is engaged in the discovery, development, manufacture and marketing a range of pharmaceutical products such as enzymes, seratrodast, allergic drugs, vaccines, antihypertensive drugs and other pharmaceuticals. The company also manufactures and markets other products including photographic and inorganic chemicals, vitamins, test reagents and clinical diagnostics. Takeda markets its in- house ethical drugs in around 90 countries. Takeda primarily operates in Japan. It is headquartered in Osaka, Japan and employs about 15,700 people. Page 1 of 2 Takeda Pharmaceutical Co. Ltd. Strengths, Weaknesses, Opportunities and Threats (SWOT) Location of Factor TYPE OF FACTOR Favorable Unfavorable Internal Strengths Weaknesses Profitable position as Heavy dependency the largest drug maker on its four in Japan blockbuster Blockbuster offerings therapeutics spanning four All four of Takeda’s therapeutic disciplines blockbusters will Strategically placed in see patent expiries endocrinology market by 2012 Strong US positioning Abundance of drugs in late-stage development External Opportunities Threats Actos could capitalize Japanese of the collapse of its healthcare reforms principal competitor, encourage generic GSK’s Avandia prescribing Scope to enhance its Increasing biologic positioning, penetration of particularly in Japanese market monoclonal antibody by western players development Page 2 of 2